Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

A Quietly Busy Senomyx

While shares of small-cap food biotech Senomyx (NASDAQ:SNMX) have pulled back almost 30% from my last piece as enthusiasm has faded in the wake of securing GRAS determination for key product Sweetmyx S617, they're still up more than 50% from my Top Idea write-up in 2013. More importantly, Senomyx continues to make significant progress with its developmental and commercial programs. Although Senomyx shares may well get batted around this year as the market vacillates between risk-on and risk-off, the significant potential of the company's sweet and savory programs is a good reason to buy or continue holding the shares.

Earnings Are Not A Driver Yet

Senomyx reported second quarter earnings on Thursday, July 31, but the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details